Loading...
Loading...
The first quarter earnings of Gilead Sciences, Inc.
GILD may miss Street view, but promising Hep C Rx trends drive a positive outlook, according to a note from Baird.
Analyst Brian Skorney said: "Our estimate for pro forma fully diluted EPS is $2.92 versus consensus at $3.12. We think this is largely due to differences in Hep C estimates but believe strong HIV sales and a recent uptick in U.S. Hep C Rx trends will maintain the stock's recent strength."
Skorney, who has an Outperform rating and $135 target price on GILD shares, noted that though "we expect Hep C sales in the U.S. to be roughly flat quarter-over-quarter (~$2.32B vs. 2.37B in 4Q15), recent trends in scripts have shown promise for an uptick in sales in 2Q."
He continued: "In March, new prescriptions popped up to levels not seen since last spring. Further, the launch of Merck & Co., Inc.
MRK 's Zepatier, has been uninspiring, diminishing competitive concerns."
"If anything, this quarter's Hep C scripts are indicative of Gilead's continued stronghold in Hep C, and leveling off of the Hep C market in the U.S. In addition, U.S. Hep C could be bolstered by the renewed VA budget this quarter," he added.
The analyst estimates total Hep C sales in Europe of $1.0 billion versus $846 million last quarter, driven by "improved access and reimbursement in key countries, such as the UK in late 2015."
In addition, Skorney expects strong performance from HIV-1 treatment Genvoya.
"Script data thus far, has implied that Genvoya's launch is set to significanly outpace that of Stribild. We are projecting sales of $90M versus consensus estimates of $70M for the drug's first full quarter on the market," the analyst added.
Shares of Gilead Sciences were up 0.22 percent to $96.04. They have dropped 6 percent this year.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in